Compare Stocks: FDMT, RCUS, NAMS, and SLS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FDMT 4D Molecular Therapeutics	$11.90 -6.9%	$13.72	$6.96 ▼ $16.93	$657.40M	2.75	1.05 million shs	683,488 shs
NAMS NewAmsterdam Pharma	$20.06 -3.4%	$22.86	$19.13 ▼ $42.21	$2.40B	0.1	1.41 million shs	1.14 million shs
RCUS Arcus Biosciences	$18.20 -2.2%	$24.97	$17.43 ▼ $31.74	$2.32B	0.94	2.57 million shs	1.94 million shs
SLS SELLAS Life Sciences Group	$9.68 -4.6%	$12.16	$1.39 ▼ $15.88	$1.95B	2.56	6.62 million shs	6.13 million shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FDMT 4D Molecular Therapeutics	0.00%	+10.19%	-14.02%	+16.90%	+4.29%
NAMS NewAmsterdam Pharma	0.00%	+1.78%	-16.97%	-27.82%	-44.01%
RCUS Arcus Biosciences	0.00%	-1.86%	-27.75%	-35.42%	-10.04%
SLS SELLAS Life Sciences Group	0.00%	-16.12%	-14.56%	-3.30%	+365.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FDMT 4D Molecular Therapeutics	$11.90 -6.9%	$13.72	$6.96 ▼ $16.93	$657.40M	2.75	1.05 million shs	683,488 shs
NAMS NewAmsterdam Pharma	$20.06 -3.4%	$22.86	$19.13 ▼ $42.21	$2.40B	0.1	1.41 million shs	1.14 million shs
RCUS Arcus Biosciences	$18.20 -2.2%	$24.97	$17.43 ▼ $31.74	$2.32B	0.94	2.57 million shs	1.94 million shs
SLS SELLAS Life Sciences Group	$9.68 -4.6%	$12.16	$1.39 ▼ $15.88	$1.95B	2.56	6.62 million shs	6.13 million shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FDMT 4D Molecular Therapeutics	0.00%	+10.19%	-14.02%	+16.90%	+4.29%
NAMS NewAmsterdam Pharma	0.00%	+1.78%	-16.97%	-27.82%	-44.01%
RCUS Arcus Biosciences	0.00%	-1.86%	-27.75%	-35.42%	-10.04%
SLS SELLAS Life Sciences Group	0.00%	-16.12%	-14.56%	-3.30%	+365.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FDMT 4D Molecular Therapeutics	2.75	Moderate Buy	$30.22	153.97% Upside
NAMS NewAmsterdam Pharma	2.83	Moderate Buy	$48.90	143.77% Upside
RCUS Arcus Biosciences	2.69	Moderate Buy	$39.64	117.81% Upside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	3.31% Upside

Current Analyst Ratings Breakdown

Latest FDMT, RCUS, NAMS, and SLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/22/2026	FDMT 4D Molecular Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/22/2026	FDMT 4D Molecular Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$36.00
10/21/2026	RCUS Arcus Biosciences	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$45.00 ➝ $50.00
10/21/2026	RCUS Arcus Biosciences	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$40.00 ➝ $41.00
10/21/2026	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$43.00 ➝ $49.00
10/16/2026	RCUS Arcus Biosciences	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/15/2026	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	NAMS NewAmsterdam Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	RCUS Arcus Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	SLS SELLAS Life Sciences Group	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/14/2026	RCUS Arcus Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$41.00

(Data available from 11/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FDMT 4D Molecular Therapeutics	$85.21M	7.71	N/A	N/A	$8.85 per share	1.34
NAMS NewAmsterdam Pharma	$22.50M	106.58	N/A	N/A	$5.97 per share	3.36
RCUS Arcus Biosciences	$247M	9.38	N/A	N/A	$5.84 per share	3.12
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FDMT 4D Molecular Therapeutics	-$140.11M	-$2.63	N/A	N/A	N/A	-194.74%	-41.33%	-35.90%	11/10/2026 (Estimated)
NAMS NewAmsterdam Pharma	-$203.82M	-$2.16	N/A	N/A	N/A	-3,644.21%	-34.81%	-31.50%	11/4/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.90	N/A	N/A	N/A	-393.16%	-89.54%	-45.61%	11/4/2026 (Estimated)
SLS SELLAS Life Sciences Group	-$26.86M	-$0.21	N/A	N/A	N/A	N/A	-35.91%	-33.34%	11/18/2026 (Estimated)

Latest FDMT, RCUS, NAMS, and SLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/18/2026	Q3 2026	SLS SELLAS Life Sciences Group	-$0.05	N/A	N/A	N/A	N/A	N/A
11/10/2026	Q3 2026	FDMT 4D Molecular Therapeutics	-$1.04	N/A	N/A	N/A	$4.13 million	N/A
11/4/2026	Q3 2026	NAMS NewAmsterdam Pharma	-$0.4949	N/A	N/A	N/A	$7.54 million	N/A
11/4/2026	Q3 2026	RCUS Arcus Biosciences	-$0.8908	N/A	N/A	N/A	$7.58 million	N/A
8/13/2026	Q2 2026	FDMT 4D Molecular Therapeutics	-$1.02	-$1.04	-$0.02	-$1.04	$3.62 million	$3.78 million
8/11/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	-$0.05	-$0.0050	-$0.05	N/A	N/A
8/5/2026	Q2 2026	NAMS NewAmsterdam Pharma	-$0.4819	-$0.52	-$0.0381	-$0.52	$2.83 million	$3.70 million
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	-$0.72	+$0.1712	-$0.72	$21.98 million	$41.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FDMT 4D Molecular Therapeutics	0.05	8.03	8.03
NAMS NewAmsterdam Pharma	N/A	9.03	9.03
RCUS Arcus Biosciences	0.22	3.82	3.82
SLS SELLAS Life Sciences Group	N/A	18.83	18.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FDMT 4D Molecular Therapeutics	99.27%
NAMS NewAmsterdam Pharma	89.89%
RCUS Arcus Biosciences	92.89%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
FDMT 4D Molecular Therapeutics	7.90%
NAMS NewAmsterdam Pharma	12.74%
RCUS Arcus Biosciences	7.60%
SLS SELLAS Life Sciences Group	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FDMT 4D Molecular Therapeutics	196	55.24 million	50.88 million	Optionable
NAMS NewAmsterdam Pharma	100	119.54 million	104.31 million	Optionable
RCUS Arcus Biosciences	601	127.33 million	117.66 million	Optionable
SLS SELLAS Life Sciences Group	13	201.95 million	199.32 million	Optionable

FDMT, RCUS, NAMS, and SLS Headlines

Recent News About These Companies

Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH), Bausch + Lomb Corporation (BLCO) and SELLAS Life Sciences Group (SLS)

October 30 at 10:48 PM | theglobeandmail.com

SELLAS Life Sciences Group (SLS) Dropped, So What Is Behind The Latest Attention?

October 29 at 8:30 PM | finance.yahoo.com

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Sees Heavy Call Option Buying

October 29 at 2:59 PM | marketbeat.com

SLS Stock’s Big AML Trial Milestone Sparks A Selloff — What’s Fueling Retail’s ‘Extremely Bullish’ Bets?

October 29 at 3:52 AM | stocktwits.comS

Sellas Sinks 18% as Phase 3 Leukemia Trial Reaches “Critical Milestone” Ahead of Final Data

October 28, 2026 | finance.yahoo.com

Sellas Life Sciences: The Longer The Wait, The More Likely A REGAL Failure

October 28, 2026 | seekingalpha.com

SELLAS Life Sciences Stock Falls 17% After Announcement Of Phase 3 REGAL Trial Milestone

October 28, 2026 | rttnews.com

Sellas falls as REGAL trial nears final analysis

October 28, 2026 | seekingalpha.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 15.4% - Here's What Happened

October 28, 2026 | marketbeat.com

SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia

October 28, 2026 | globenewswire.com

SLS stock gets a BlackRock spotlight ahead of phase 3 AML data — bulls spot 2027 European GPS approval forecast

October 28, 2026 | msn.com

Sellas Life Sciences: Too Many Survivors For Its Own Trial Plan

October 26, 2026 | seekingalpha.com

SELLAS Life Sciences Group, Inc. $SLS Stock Holdings Lifted by Dagco Inc.

October 20, 2026 | marketbeat.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down - What's Next?

October 20, 2026 | marketbeat.com

SELLAS Life Sciences Group Inc.

October 20, 2026 | barrons.com

SLS stock jumps overnight: Retail eyes huge potential buyout as CEO marks 15 years

October 20, 2026 | msn.com

SLS Stock Climbs Pre-Market: CEO's Early Anniversary Post Has Retail Bulls Buzzing About Major News

October 19, 2026 | stocktwits.comS

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Jumps 7.4% - Here's Why

October 19, 2026 | marketbeat.com

SLS stock logs worst week in over a month: Retail bulls bet ASH embargo is keeping Regal results under wraps

October 19, 2026 | msn.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 11.2% – Here’s What Happened

October 18, 2026 | defenseworld.netD

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Falls 11.2% - Should You Sell?

October 16, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT, RCUS, NAMS, and SLS Company Descriptions

4D Molecular Therapeutics NASDAQ:FDMT

$11.90 -0.88 (-6.89%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$11.75 -0.15 (-1.28%)

As of 10/30/2026 07:57 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

NewAmsterdam Pharma NASDAQ:NAMS

$20.06 -0.70 (-3.37%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$19.55 -0.51 (-2.54%)

As of 10/30/2026 07:30 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Arcus Biosciences NYSE:RCUS

$18.20 -0.41 (-2.21%)

Closing price 10/30/2026 03:59 PM Eastern

Extended Trading

$18.18 -0.02 (-0.10%)

As of 10/30/2026 07:30 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

SELLAS Life Sciences Group NASDAQ:SLS

$9.68 -0.47 (-4.63%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$9.64 -0.04 (-0.36%)

As of 10/30/2026 07:59 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FDMT, RCUS, NAMS, and SLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FDMT, RCUS, NAMS, and SLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FDMT, RCUS, NAMS, and SLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT, RCUS, NAMS, and SLS Company Descriptions

4D Molecular Therapeutics NASDAQ:FDMT

NewAmsterdam Pharma NASDAQ:NAMS

Arcus Biosciences NYSE:RCUS

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FDMT, RCUS, NAMS, and SLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FDMT, RCUS, NAMS, and SLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FDMT, RCUS, NAMS, and SLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT, RCUS, NAMS, and SLS Company Descriptions

4D Molecular Therapeutics NASDAQ:FDMT

NewAmsterdam Pharma NASDAQ:NAMS

Arcus Biosciences NYSE:RCUS

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools